Abstract

The ethyl acetate fraction of Quercus incana yielded two new compounds [1 and 2]. The characterization and structure elucidation of these compounds were carried out through various spectroscopic techniques such as mass spectrometry along with one- and two-dimensional NMR techniques. The structural formula was deduced to be 2-(4-hydroxybutan-2-yl)-5-methoxyphenol [1] and 4-hydroxy-3-(hydroxymethyl) pentanoic acid [2]. The elevated plus maze (EPM) and light–dark box (LDB) tests (classical mouse models) were performed in order to reveal the anxiolytic potential of both compounds [1 and 2]. Both compounds displayed dose-dependent increases in open-arm entries and time spent in open arms in EPM (∗P < 0.05, ∗∗P < 0.01), and increased the time spent in the lit compartment and increased transitions between the two compartments in LDB test (∗P < 0.05, ∗∗P < 0.01). Co-administration of selective benzodiazepine (BZP) receptor antagonist, flumazenil (2.5 mg/kg) with compounds [1 and 2] decreased the anxiolytic-like activity of both compounds in the EPM indicating BZP-binding site of GABA-A receptors are involved in the anxiolytic-like effect. Similarly, both compounds at the dose level of 10 and 30 mg/kg, i.p. exerted pronounced antidepressant-like effect in both forced swimming as well as tail suspension tests (∗P < 0.05, ∗∗P < 0.01; ANOVA followed by Dunnett’s post hoc test). The effect at 30 mg/kg was comparable to the reference drug imipramine (60 mg/kg).

Highlights

  • Stress is known to play a significant part in pathogenesis of mental dysfunctions (Kalueff and Tuohimaa, 2004)

  • Fraction B was loaded on silica gel and eluted with EtOAc: n-hexane (70:30) to get compound 1 while compound 2 was purified at EtOAc: n-hexane (85:15), respectively

  • The methylene signal bearing hydroxyl group resonated at δH 3.39 (1H, m, H-1 ), δH 3.68 (1H, m, H-1 ) and the other methylene signal appeared at δH 1.53 (1H, m, H-2 ), δH 2.01 (1H, m, H-2 )

Read more

Summary

Introduction

Stress is known to play a significant part in pathogenesis of mental dysfunctions (Kalueff and Tuohimaa, 2004). Depression is associated with disease causing pain, disability, deformity, and conditions, which may reduce patient’s quality of life and life expectancy. A number of antidepressant drugs are clinically available, which presumably act via different mechanisms, including the noradrenergic, serotonergic, and/or dopaminergic systems. These drugs include monoamine oxidase inhibitors, tricyclic antidepressant drugs, selective serotonin reuptake inhibitors (SSRIs), and serotonin–norepinephrine reuptake inhibitors (SNRIs) (Gonçalves et al, 2012; Khan et al, 2016). These agents have their limitations including inadequate effectiveness over a prolonged period and unwanted side effects (Berton and Nestler, 2006). There has been a renewed interest in natural compounds, from plants that mitigate anxiety and depressive-like symptoms (González-Trujano et al, 2017)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call